What is Candel Therapeutics?
Candel Therapeutics operates at the intersection of oncology and immunology, specializing in the development of viral immunotherapies designed to trigger systemic anti-cancer responses. The company's core technology focuses on inducing in situ vaccination, which prompts the immune system to recognize and attack unique tumor antigens and neoantigens. By stimulating both innate and adaptive immune mechanisms, Candel aims to generate a durable, patient-specific T cell response. This approach is engineered to address not only the primary tumor site but also uninjected metastases, offering a transformative potential for clinical outcomes across a diverse spectrum of cancer indications.
How much funding has Candel Therapeutics raised?
Candel Therapeutics has raised a total of $195.4M across 4 funding rounds:
Series A
$14.2M
Series B
$28.7M
Series C
$22.5M
Debt
$130M
Series A (2016): $14.2M with participation from National Securities Corporation
Series B (2019): $28.7M led by PBM Capital
Series C (2019): $22.5M, investors not publicly disclosed
Debt (2025): $130M featuring Trinity Capital
Key Investors in Candel Therapeutics
National Securities Corporation
A full-service wealth management firm providing comprehensive brokerage, investment management, and consultative financial advisory services to a diverse client base.
PBM Capital
An investment entity with a background in supporting high-standard consumer and healthcare-related enterprises through rigorous financial oversight.
Trinity Capital
A banking and financial services firm specializing in lending, investment management, and advisory solutions for corporate and individual clients.
What's next for Candel Therapeutics?
With the recent influx of capital, Candel Therapeutics is well-positioned to accelerate its clinical pipeline and scale its manufacturing capabilities. The strategic deployment of these funds will likely focus on advancing late-stage trials and refining the delivery mechanisms of its viral vectors. As the company moves deeper into the enterprise-level growth phase, the focus will shift toward regulatory milestones and potential commercialization strategies. Investors and industry observers will be monitoring the firm's ability to translate its individualized immunotherapy results into broader therapeutic standards, effectively navigating the competitive landscape of precision medicine and oncology-focused biotechnology.
See full Candel Therapeutics company page
